[Results of Befnorin clinical trails in healthy volunteers].
Clinical trails of Befnorin based on the human recombinant TNF-beta elaborated at the Research Design and Technology Institute of Biologically Active Substances, "Vector" State Research Center of Virology and Biotechnology, were carried out on healthy volunteers in compliance with a decision passed by the Committee of Medical and Immunobiological Preparations, Russia's Health Ministry. Single Befnorin doses of 5-10(4) U, 10(5) U, 5-10(5) U, and 10(6) U were administered as intramuscular injections. Clinical, biochemical and immunological parameters were registered for 7 days after a single dose. The drug had an impact on the below immunity indices: Fc-phagocytosis of monocytes, migration index and migration inhibition index. The dose of 10(5) U was proven to be most effective and safe. Supposedly, the drug can be effective in the treatment of herpetic diseases.
Masycheva
V I
VI
Shirinskiĭ
V S
VS
Starostina
N M
NM
Kozhevnikov
V S
VS
Meledina
I V
IV
Novikova
L M
LM
Meniaeva
E V
EV
Kristosova
N V
NV
Shevchuk
N I
NI
Evsiukova
E V
EV
Danilenko
E D
ED
Pustoshilova
N M
NM
Kozlov
V A
VA
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000009:adverse effects*; D000293:Adolescent; D000328:Adult; D004305:Dose-Response Relationship, Drug; D005334:Fever / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006562:Herpes Zoster / Q000276:immunology; D006801:Humans; D007273:Injections, Intramuscular; D008214:Lymphocytes / Q000187:drug effects; D008233:Lymphotoxin-alpha / Q000008:administration & dosage* / Q000009:adverse effects*; D008875:Middle Aged; D010587:Phagocytosis / Q000187:drug effects; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects
D000276:Adjuvants, Immunologic; D008233:Lymphotoxin-alpha; D011994:Recombinant Proteins